Manoj Garg

Jump to

Pharma policy to impact cos; buy Lupin, Cipla: Edelweiss

Manoj Garg of Edelweiss Securities believes it is a balanced policy and will help to reduce prices by about 15-20 percent. In some cases, it might even be lowered by as much as 40-50 percent.
Ranbaxy face value at Rs 510-520; exit on rally: Edelweiss

In an interview to CNBC-TV18, Manoj Garg, VP, institutional equities – research of Edelweiss Securities says, one should exit Ranbaxy on rally. “The face value of the stock would be in the vicinity of around Rs 510-520.”
Post Q1, which stocks hit & missed in the pharma sector

In an interview on CNBC-TV18, Sarabjit Kour Nangra, VP - Research, Angel Broking Ltd and Manoj Garg, Institutional Equities - Research, Edelweiss Securities give a detailed view on how to play select stocks in the pharma sector.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Manoj Garg

Pharma policy to impact cos; buy Lupin, Cipla: Edelweiss

Ranbaxy face value at Rs 510-520; exit on rally: Edelweiss

Post Q1, which stocks hit & missed in the pharma sector